Abstract: The present disclosure provides a kit and method for constructing a long-acting depression animal model. The present disclosure adopts Bacille Calmette-Guerin (BCG) (or Mycobacterium bovis (M bovis)) and low-dose pertussis toxin (PTX) for combined induction, which greatly reduces modeling cost. A mouse model constructed by the method of the present disclosure can clearly distinguish a time interval of pathological behaviors from a time interval of depression-like behaviors and has prominent face validity and predictive validity. The method of the present disclosure is simple and convenient and does not require a large number of tedious daily operations as the depression model construction by chronic unpredictable stress, chronic restraint stress, social defeat, mother-child separation, or the like. The mouse model of the present disclosure can provide a valuable long-term intervention window for research on antidepressant therapy.

Abstract: The present disclosure provides a kit and method for constructing a long-acting depression animal model. The present disclosure adopts Bacille Calmette-Guerin (BCG) (or Mycobacterium bovis (M. bovis)) and low-dose pertussis toxin (PTX) for combined induction, which greatly reduces modeling cost. A mouse model constructed by the method of the present disclosure can clearly distinguish a time interval of pathological behaviors from a time interval of depression-like behaviors and has prominent face validity and predictive validity. The method of the present disclosure is simple and convenient and does not require a large number of tedious daily operations as the depression model construction by chronic unpredictable stress, chronic restraint stress, social defeat, mother-child separation, or the like. The mouse model of the present disclosure can provide a valuable long-term intervention window for research on antidepressant therapy.

Abstract: The disclosure provides an application of an anthocyanin extract in preparing a pharmaceutical composition for preventing and treating cardiac toxicity induced by Anthracyclines and the pharmaceutical composition, wherein the pharmaceutical composition comprises an effective dose of the anthocyanin extract; and the anthocyanin extract refers to an extract obtained from mature fruits of a zygophyllaceous nitraria plant and having a total anthocyanin content greater than 700 mg CGE/g and a total antioxidant capacity greater than 200 mg TE/g. Cytobiology and molecular biology studies prove that the anthocyanin extract has obvious protection effect to cardiomyocyte toxicity damage induced by anthracyclines and may be used for preventing and alleviating cardiotoxicity of an antharcyclines anticancer drug, thereby expanding a clinical application of the antharcyclines anticancer drug and relieving toxic and side effects brought by the antharcyclines anticancer drug to a patient and pain of a chemotherapy patient.

Abstract: The disclosure provides an application of an anthocyanin extract in preparing a pharmaceutical composition for preventing and treating cardiac toxicity induced by Anthracyclines and the pharmaceutical composition, wherein the pharmaceutical composition comprises an effective dose of the anthocyanin extract; and the anthocyanin extract refers to an extract obtained from mature fruits of a zygophyllaceous nitraria plant and having a total anthocyanin content greater than 700 mg CGE/g and a total antioxidant capacity greater than 200 mg TE/g. Cytobiology and molecular biology studies prove that the anthocyanin extract has obvious protection effect to cardiomyocyte toxicity damage induced by anthracyclines and may be used for preventing and alleviating cardiotoxicity of an antharcyclines anticancer drug, thereby expanding a clinical application of the antharcyclines anticancer drug and relieving toxic and side effects brought by the antharcyclines anticancer drug to a patient and pain of a chemotherapy patient.